Bristol Myers Squibb secures expanded US approval for Camzyos
The regulatory decision was supported by findings from the randomised Phase III SCOUT-HCM trial in 44 adolescent patients.
Drug Development
BioMarin and Profluent partner on AI-designed enzyme therapies
OBIO marks $704m funding milestone for Canadian health tech ventures
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
AstraZeneca to invest $2bn in Summit for ADC combination therapies
Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma
Mirum and Incyte’s Atebrioz approved for FOP in US
Amberstone and Henlius agree to develop solid-tumour T-cell engagers
